NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced it has resubmitted its ...
–TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of ...
NEWPORT BEACH, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, is thrilled to share that strategic partner, Chong Kun Dang Bio (063160:Korea SE), ...
Please provide your email address to receive an email when new articles are posted on . New phase 2 results showed 40 units of Jeuveau sustained improvements in glabellar lines up to 6 months. Adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results